文拉法辛治疗焦虑抑郁共病对照研究

目的：探讨文拉法辛与帕罗西汀治疗焦虑抑郁共病障碍的疗效及安全性。方法：73例焦虑抑郁共病障碍患者随机分为研究组35例和对照组38例。分别给予文拉法辛和帕罗西汀治疗8周。于治疗前后分别采用汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表（HAMD）及治疗中出现的症状量表（TESS）评定疗效和不良反应。结果：两组抗抑郁显效率（χ2=0.69,P〉0.05）和抗焦虑显效率（χ2=0.90,P〉0.05）相仿。两组HAMD、HAMA治疗后均显著下降（P〈0.05或P〈0.01）。不良反应均轻微（P〉0.05）。结论：文拉法辛与帕罗西汀治疗焦虑抑郁共病障碍疗效肯定,安全性高,依从性好。

Controlled study on depression comorbid with anxiety treated by venlafaxine

Objective：To detect the efficacy and safety of venlafaxine and proxetine in the treatment of depression comorbid with anxiety.Method：73 patients with anxiety and depression were divided randomly into two groups（35 cases in study group;38 cases in control group）.The study group was taken venlafaxine,and the control group was taken paroxitine.They were observed for 8 weeks.Hamilton depression scale（HAMD）,Hamilton anxiety scale（HAMA）and treatment emergent symptoms scale（TESS）were used to evaluate the efficacies and side effects.Results：After 8 weeks treatment,study group showed improvement rate for depression and for anxiety which was similar to in control group（χ2=0.69,0.90;P〈0.05）.The two groups showed significant decreases on HAMD and HAMA scores（P〈0.05 or P〈0.01）and light side effects.Conclusion：Venlafaxine and paroxitine have definite efficacy and safety for combined anxiety and depression with better patients＇ compliance.